Healthcare / Medical Instruments & SuppliesBSE
$55.50
-1.95 (-3.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-13.9M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
57/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$480M
P/E
13.7x
↓EV/EBITDA
8.8x
↓ROE
13.9%
↑Gross Margin
31.6%
↓Debt/Equity
0.11
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.7%
FCF CAGR
—
FCF margin
-7.3%
FCF / Net income
-0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $383.9M · net income $33.4M · FCF $-27.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $383.9M | $383.9M | $310.7M | $278.6M | $365.0M |
| Net Income | $33.4M | $33.4M | $26.3M | $15.1M | $14.7M |
| EBITDA | $54.4M | $54.4M | $45.8M | $35.1M | $29.6M |
| EPS | 3.96 | 3.96 | 3.04 | 1.74 | 1.69 |
| Gross Margin | 31.6% | 31.6% | 28.8% | 26.4% | 23.2% |
| Operating Margin | 8.6% | 8.6% | 8.9% | 8.8% | 5.9% |
| Net Margin | 8.7% | 8.7% | 8.5% | 5.4% | 4.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.11 | 0.11 | — | 0.61 | 0.70 |
| Current Ratio | 3.29 | 3.29 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-27.9M | $-27.9M | $-13.9M | $9.5M | $-24.0M |
| Returns | |||||
| ROE | 13.9% | 13.9% | — | 19.6% | 23.6% |
| Valuation | |||||
| P/E | 13.70 | 13.70 | — | — | — |
| EV/EBITDA | 8.80 | 8.80 | — | — | — |
| P/B | 1.94 | 1.94 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 23.6% | 23.6% | 11.5% | -23.7% | — |
| EPS Growth | 30.3% | 30.3% | 74.1% | 2.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
7.5%
EPS terminal req.
$4.92
Spread vs growth
22.8%
5Y implied EPS CAGR
8.5%
EPS terminal req.
$5.96
Spread vs growth
21.8%
10Y implied EPS CAGR
9.3%
EPS terminal req.
$9.60
Spread vs growth
21.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+23.3%
Start / end P/E
14.8x → 14.0x
EPS bridge
3.04 → 3.96
Residual
-1.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.